• Policy
• Lee to pledge ‘incentives for homegrown new drugs'
• by Lee, Jeong-Hwan Feb 16, 2022 05:51am

• Company
• GC Pharma & SK Bioscience are competing
• by Ji Yong Jun Feb 16, 2022 05:51am

• Company
• Amgen’s Lumakras approved in Korea… first-ever approved
• by Feb 16, 2022 05:51am

• Policy
• There's plenty of COVID-19 PO medicine, Regkirona
• by Lee, Jeong-Hwan Feb 16, 2022 05:51am

• Company
• The paradox of COVID-19
• by Kim, Jin-Gu Feb 15, 2022 05:54am

• Company
• Drug pricing negotiations for ‘Xospata’ complete
• by Eo, Yun-Ho Feb 15, 2022 05:54am

• Company
• The next Saxenda? Companies race to occupy GLP-1 RA market
• by Feb 15, 2022 05:54am

• Company
• Takeda, Boehringer, & AZ were selected as the Best Companies
• by Eo, Yun-Ho Feb 15, 2022 05:53am

• Company
• Changes in sales and marketing of companies
• by Moon, sung-ho Feb 15, 2022 05:53am

• Company
• The era of personalized healthcare has arrived
• by Eo, Yun-Ho Feb 14, 2022 05:54am